## Supplementary file

Authors: Paulo Ricardo Martins-Filho, Lis Campos Ferreira, Luana Heimfarth, Adriano Antunes de Souza Araújo, Lucindo José Quintans-Júnior.

Title: Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.

### Search strategy

### PubMed:

(Chloroquine OR Chlorochin OR Arequin OR Aralen OR Arechine OR Nivaquine OR Chingamin OR Hydroxychloroquine OR Hydroxychlorochin OR Oxychlorochin OR Plaquenil) AND (COVID-19 OR "2019-nCoV Infection" OR "Coronavirus Disease-19" OR "2019-nCoV Disease" OR SARS-CoV-2) AND (randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract] AND trial[Title/Abstract]))

### Embase:

(Chloroquine OR Chlorochin OR Arequin OR Aralen OR Arechine OR Nivaquine OR Chingamin OR Hydroxychloroquine OR Hydroxychlorochin OR Oxychlorochin OR Plaquenil) AND (COVID-19 OR "2019-nCoV Infection" OR "Coronavirus Disease-19" OR "2019-nCoV Disease" OR SARS-CoV-2) AND ('crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled trial':de OR 'single-blind procedure':de OR (random\* OR factorial\* OR crossover\* OR cross NEXT/1 over\* OR placebo\* OR doubl\* NEAR/1 blind\* OR singl\* NEAR/1 blind\* OR assign\* OR allocat\* OR volunteer\*):de,ab,ti)

### Web of Science:

(Chloroquine OR Chlorochin OR Arequin OR Aralen OR Arechine OR Nivaquine OR Chingamin OR Hydroxychloroquine OR Hydroxychlorochin OR Oxychlorochin OR Plaquenil) AND (COVID-19 OR "2019-nCoV Infection" OR "Coronavirus Disease-19" OR "2019-nCoV Disease" OR SARS-CoV-2) AND (TS= clinical trial\* OR TS=research design OR TS=comparative stud\* OR TS=evaluation stud\* OR TS=controlled trial\* OR TS=follow-up stud\* OR TS=prospective stud\* OR TS=random\* OR TS=placebo\* OR TS=(single blind\*) OR TS=(double blind\*))

#### Lilacs:

(Chloroquine OR Chlorochin OR Arequin OR Aralen OR Arechine OR Nivaquine OR Chingamin OR Hydroxychloroquine OR Hydroxychlorochin OR Oxychlorochin OR Plaquenil) AND (COVID-19 OR "2019-nCoV Infection" OR "Coronavirus Disease-19" OR "2019-nCoV Disease" OR SARS-CoV-2) AND ("clinical trial" OR placebo OR "controlled trial" OR "double blind")

## medRxiv:

(Chloroquine OR Hydroxychloroquine) AND (COVID-19 OR SARS-CoV-2) AND ("clinical trial" OR placebo OR "controlled trial")

# Hydroxychloroquine as pre-exposure prophylaxis to prevent SARS-CoV-2 infection

Table S1. Blinded, placebo-controlled, randomized clinical trials evaluating the efficacy and safety of hydroxychloroquine as prophylactic medication pre-exposure to COVID-19.

Author	Study	Country	Protocol and Phase	Population	Intervention	Control	Outcomes of interest (Time of evaluation)
Abella	Efficacy and Safety of	USA	NCT04329923	Healthcare workers at high-	HCQ 600mg/day for 8 weeks	Placebo	Incidence of SARS-CoV-2
2021	Hydroxychloroquine vs Placebo for Pre- exposure SARS-cov-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial		(Phase 2)	risk for SARS-CoV-2 infection	(n = 66)	(n = 66)	infection and adverse events (8 weeks)
Rojas-Serrano 2021	Hydroxychloroquine for Prophylaxis Of COVID-19 in Health Workers: A Randomized Clinical Trial	Mexico	NCT04318015 (Phase 3)	Healthcare workers at high- risk for SARS-CoV-2 infection	HCQ 200mg/day for 8 weeks (n = 62)	Placebo (n = 65)	Incidence of SARS-CoV-2 infection and adverse events (8 weeks)
Syed 2021	Pre-Exposure Prophylaxis with Various Doses of Hydroxychloroquine among high-risk COVID 19 Healthcare Personnel: CHEER randomized controlled trial	Pakistan	NCT04359537 (Phase 2)	Healthcare workers at high- risk for SARS-CoV-2 infection	A: HCQ 400mg, 2x/day in the first day + 400mg 1x/week for 12 weeks B: HCQ 400mg, once every 3 weeks C: HCQ 200mg, once every 3 weeks (A: n = 48) (B: n = 51) (C: n = 55)	Placebo (n = 46)	Incidence of SARS-CoV-2 infection and adverse events (12 weeks)
Rajasingham 2020	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial	USA and Canada	NCT04328467 (Phase 3)	Healthcare workers at high- risk for SARS-CoV-2 infection	A: HCQ 400mg loading dose + 400mg 1x/week for 12 weeks B: HCQ 400mg loading dose + 400mg 2x/weeks for 12 weeks (A: n = 494) (B: n = 495)	Placebo (n = 494)	Incidence of SARS-CoV-2 infection and adverse events (12 weeks)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Sample size calculation, power analysis, and early stopping for futility (operational bias)	Outcome measurements (information bias)	Conflict of interest
Abella 2021	•	•	•	?	•	•	•	•	?
Rajasingham 2020	?	•	•	•	•	•		•	?
Rojas-Serrano 2021	•	•	•	•	•	•		•	?
Syed 2021	•	?	•		•			•	?

Fig. S1. Risk of bias assessment on the use of hydroxychloroquine as prophylactic medication pre-exposure to COVID-19.

Table S2. Individual results of studies evaluating the efficacy and safety of hydroxychloroquine as prophylactic medication pre-exposure to COVID-19.

Author	Cases of COVID-19	Any adverse events	Conclusion
Abella	HCQ: 4/64 (6.3%)	HCQ: 29/65 (44.6%)	"There was no clinical benefit of hydroxychloroquine administered
2021	Placebo: 4/61 (6.6%)	Placebo: 17/65 (26.2%)	daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19."
Rojas-Serrano	HCQ: 1/62 (1.6%)	HCQ: 32/62 (51.6%)	"No beneficial effect or significant harm could be demonstrated in our
2021	Placebo: 6/65 (9.2%)	Placebo: 38/65 (58.5%)	randomized controlled trial including 127 participants, using relatively low doses of HCQ compared with placebo in health personnel."
Syed	A: HCQ 400mg, 1x/week: 15/48 (31.3%)	A: HCQ 400mg, 1x/week: 5/48 (10.4%)	"There was no significant reduction in the SARS-CoV-2 transmission
2021	B: 400mg, once every 3 weeks: 19/51 (37.3%) C: 200mg, once every 3 weeks: 8/55 (14.5%) Placebo: 7/46 (15.2%)	B: 400mg, once every 3 weeks: 1/51 (2.0%) C: 200mg, once every 3 weeks: 3/55 (5.5%) Placebo: 1/46 (2.2%)	with PrEP administration of hydroxychloroquine among the enrolled healthcare personnel."
Rajasingham	A: HCQ 400mg, 1x/week: 29/494 (5.9%)	A: HCQ 400mg, 1x/week: 148/473 (31.3%)	"Pre-exposure prophylaxis with hydroxychloroquine once or twice
2020	B: HCQ 400mg, 2x/week: 29/495 (5.9%)	B: HCQ 400mg, 2x/week: 168/463 (36.3%)	weekly did not significantly reduce laboratory-confirmed COVID-19 or
	Placebo: 39/494 (7.9%)	Placebo: 100/469 (21.3%)	COVID-19–compatible illness among healthcare workers."

	HCC	Q	Place	bo		Risk Ratio			Risk F	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-	H, Rando	m, 95% (	CI	
Abella 2021	4	64	4	61	16.7%	0.95 [0.25, 3.64]			-			
Rajasingham 2020	58	989	39	494	43.1%	0.74 [0.50, 1.10]						
Rojas-Serrano 2021	1	62	6	65	8.6%	0.17 [0.02, 1.41]		-		-		
Syed 2021	42	154	7	46	31.6%	1.79 [0.86, 3.72]			+	•		
Total (95% CI)		1269		666	100.0%	0.90 [0.46, 1.77]				-		
Total events	105		56									
Heterogeneity: Tau² = I	0.23; Chi²	= 6.69	df=3(P	= 0.08	); I <sup>z</sup> = 559	6	0.04		<del></del>		10	400
Test for overall effect: 2							0.01	0.1	HCQ	Placebo	10	100

Fig. S2. Forest plot showing the risk of SARS-CoV-2 infection for individuals using hydroxychloroquine as prophylactic medication pre-exposure to COVID-19.

	HCC	Q	Place	bo		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rand	lom, 95%	CI	
Abella 2021	29	65	17	65	25.7%	1.71 [1.04, 2.78]			-		
Rajasingham 2020	316	936	100	469	37.7%	1.58 [1.30, 1.93]			-		
Rojas-Serrano 2021	32	62	38	65	33.0%	0.88 [0.64, 1.21]		-	+		
Syed 2021	9	154	1	46	3.6%	2.69 [0.35, 20.67]			<del>                                     </del>		
Total (95% CI)		1217		645	100.0%	1.36 [0.91, 2.03]			•		
Total events	386		156								
Heterogeneity: Tau² = Test for overall effect: 2				P = 0.0	1); I² = 73	1%	0.05	0.2 Placebo	HCQ	5	20

Fig. S3. Forest plot showing the risk of any adverse events for individuals using hydroxychloroquine as prophylactic medication pre-exposure to COVID-19.

Table S3. Sensitivity analysis of studies evaluating the efficacy and safety of hydroxychloroquine as prophylactic medication pre-exposure to COVID-19.

Outcomes	RR (95% CI)	l <sup>2</sup>	Risk of bias	Inconsistency	Indirectness	Imprecision	Influence of small trials	Large effect	Quality of evidence
SARS-CoV-2 infection									
Peer-reviewed studies	0.76 (0.52 to 1.10)	0%	Not serious	Not serious	Not serious	Serious	Not serious	No	$\oplus \oplus \oplus \bigcirc$
Non-peer reviewed studies	0.69 (0.07 to 6.73)	77%	Serious	Serious	Not serious	Serious	Strongly suspect	No	$\oplus$
Any adverse events									
Peer-reviewed studies	1.60 (1.33 to 1.92)	0%	Serious	Not serious	Not serious	Not serious	Not serious	No	$\oplus \oplus \oplus \oplus$
Non-peer reviewed studies	1.00 (0.49 to 2.05)	18%	Serious	Serious	Not serious	Serious	Not serious	No	ФООО

Certainty: ⊕ very-low; ⊕⊕ low; ⊕⊕⊕ moderate; ⊕⊕⊕⊕ high.

# Hydroxychloroquine as post-exposure prophylaxis to prevent SARS-CoV-2 infection

Table S4. Blinded, placebo-controlled, randomized clinical trials evaluating the efficacy and safety of hydroxychloroquine as prophylactic medication post-exposure to COVID-19.

Author	Study	Country	Protocol and Phase	Population	Intervention	Control	Outcomes of interest (Time of evaluation)
Barnabas	Hydroxychloroquine as Postexposure	USA	NCT04328961	Asymptomatic adults who had	HCQ 400mg/day per 3 days +	Placebo	Incidence of SARS-CoV-2
2020	Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial		(Phase 2/3)	close contact (occupational or household exposure) with a person with recent known SARS-CoV-2 infection	200mg/day for 11 days (n = 407)	(n = 422)	infection and adverse events (14 days)
Boulware 2020	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19	USA and Canada	NCT04308668 (Phase 3)	Asymptomatic adults who had close contact (occupational or household exposure) with a person with recent known SARS-CoV-2 infection	HCQ 800mg loading dose followed by 600mg in 6 to 8h + 600mg/day for 4 days (n = 414)	Placebo (n = 407)	Incidence of SARS-CoV-2 infection and adverse events (14 days)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Sample size calculation, power analysis, and early stopping for futility (operational bias)	Outcome measurements (information bias)	Conflict of interest
Barnabas 2020	•	•	•	•	•	•	•	•	?
Boulware 2020	•	•	•	•	•	•		•	?

Fig. S4. Risk of bias assessment on the use of hydroxychloroquine as prophylactic medication post-exposure to COVID-19.

Table S5. Individual results of studies evaluating the efficacy and safety of hydroxychloroquine as prophylactic medication post-exposure to COVID-19.

Author	Cases of COVID-19	Any adverse events	Conclusion
Barnabas	HCQ: 53/353 (15.0%)	HCQ: 66/407 (16.2%)	"This rigorous randomized controlled trial among persons with recent exposure
2020	Placebo: 45/336 (13.4%)	Placebo: 46/422 (10.9%)	excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection."
Boulware	HCQ: 49/414 (11.8%)	HCQ: 140/349 (40.1%)	"This randomized trial did not demonstrate a significant benefit of hydroxychloroquine
2020	Placebo: 58/407 (14.3%)	Placebo: 59/351 (16.8%)	as postexposure prophylaxis for Covid-19."

	HCC	Q	Place	bo		Risk Ratio			Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-	H, Rand	om, 95% C	<u> </u>	
Barnabas 2020	53	353	45	336	48.6%	1.12 [0.78, 1.62]				-		
Boulware 2020	49	414	58	407	51.4%	0.83 [0.58, 1.18]			-	<u> </u>		
Total (95% CI)		767		743	100.0%	0.96 [0.72, 1.29]			•			
Total events	102		103									
Heterogeneity: Tau² = Test for overall effect:				P = 0.2	5); l² = 24	%	0.01	0.1	HCQ	Placebo	10	100

Fig. S5. Forest plot showing the risk of SARS-CoV-2 infection for individuals using hydroxychloroquine as prophylactic medication post-exposure to COVID-19.

	HCC	2	Place	bo		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rand	lom, 95%	CI	
Barnabas 2020	66	407	46	422	46.9%	1.49 [1.05, 2.11]			-		
Boulware 2020	140	349	59	351	53.1%	2.39 [1.83, 3.11]			-		
Total (95% CI)		756		773	100.0%	1.91 [1.20, 3.04]			•		
Total events	206		105								
Heterogeneity: Tau² = Test for overall effect:	•			P = 0.0	4); l² = 77	%	0.01	0.1 Placebo	1 HCQ	10	100

Fig. S6. Forest plot showing the risk of any adverse events for individuals using hydroxychloroquine as prophylactic medication post-exposure to COVID-19.

# Hydroxychloroquine as treatment for non-hospitalized patients with COVID-19

Table S6. Blinded, placebo-controlled, randomized clinical trials evaluating the efficacy and safety of hydroxychloroquine as treatment for non-hospitalized patients with COVID-19.

Author	Study	Country	Protocol and Phase	Population	Intervention	Control	Outcomes of interest (Time of evaluation)
Skipper	Hydroxychloroquine in	USA and	NCT04308668	Symptomatic, non-hospitalized patients with RT-PCR diagnosis of	HCQ 800mg loading	Placebo	Hospitalization, death,
2020	Nonhospitalized Adults	Canada	(Phase 3)	COVID-19 or compatible symptoms after a high-risk exposure to a	dose followed by	(n = 211)	and adverse events
	with Early COVID-19: A			person with known COVID-19	600mg in 6 to 8h +		(14 days)
	Randomized Trial			HCQ group: median age 41y (range 33-49). Sex: 42.0% male.	600mg/day for 4 days		
				Medical conditions: hypertension 10.8%, diabetes 3.8%.	(n = 212)		
				• Placebo: median age 39y (range 31-50). Sex: 45.5% male.			
				Medical conditions: hypertension 10.9%, diabetes 3.3%.			
Reis	Effect of Early Treatment	Brazil	NCT04403100	Symptomatic, non-hospitalized patients with RT-PCR diagnosis of	HCQ 800mg loading	Placebo	Hospitalization, death,
2021	with Hydroxychloroquine		(Phase 3)	COVID-19 or a clinical condition compatible with COVID-19 and	dose + 400mg/day	(n = 227)	and adverse events
	or Lopinavir and Ritonavir			respiratory symptoms	for 9 days		(90 days)
	on Risk of Hospitalization			HCQ group: median age 53y (range 18-81). Sex: 43.0% male.	(n = 214)		
	Among Patients With			Medical conditions: hypertension 47.2%, diabetes: 19.2%,			
	COVID-19. The TOGETHER			heart disease: 2.8%.			
	Randomized Clinical Trial			• Placebo: median age 53y (range 18-80). Sex: 46.7% male.			
				Medical conditions: hypertension 48.0%, diabetes: 21.1%,			
				heart disease: 3.5%			
Johnston	Hydroxychloroquine with	USA	NCT04354428	Symptomatic (> 92%), non-hospitalized patients with RT-PCR	HCQ 400mg, 2x/day in	Placebo	Hospitalization, death,
2021	or without azithromycin for		(Phase 2/3)	diagnosis of COVID-19	the first day + 200mg,	(n = 83)	and adverse events
	treatment of early SARS-			HCQ group: median age 36y (range 19-78). Sex: 45.1% male.	2x/day for 9 days		(28 days)
	CoV-2 infection among			Medical conditions: hypertension 11.3%, diabetes 7.0%.	(n = 71)		
	high-risk outpatient adults:			• Placebo: median age 38y (range 18-70). Sex: 45.8% male.			
	A randomized clinical trial			Medical conditions: hypertension 8.4%, diabetes 6.0%.			




Fig. S7. Risk of bias assessment on the use of hydroxychloroquine as treatment for non-hospitalized patients with COVID-19.

Table S7. Individual results of studies evaluating the efficacy and safety of hydroxychloroquine as treatment for non-hospitalized patients with COVID-19.

Author	Need of hospitalization	Death	Any adverse events	Conclusion
Skipper	HCQ: 4/212 (1.9%)	HCQ: 1/212 (0.5%)	HCQ: 92/212 (43.4%)	"Hydroxychloroquine did not substantially reduce symptom
2020	Placebo: 8/211 (3.8%)	Placebo: 1/211 (0.5%)	Placebo: 46/211 (21.8%)	severity in outpatients with early, mild COVID-19."
Reis	HCQ: 8/214 (3.7%)	HCQ: 0/214	HCQ: 46/207 (22.2%)	"In this randomized clinical trial, neither hydroxychloroquine
2021	Placebo: 11/227 (4.9%)	Placebo: 1/227 (0.4%)	Placebo: 46/220 (20.9%)	nor lopinavir-ritonavir showed any significant benefit for decreasing COVID-19—associated hospitalization or other secondary clinical outcomes."
Johnston	HCQ: 2/71 (2.8%)	HCQ: 0/71	HCQ: 5/71 (7.0%)	"HCQ and HCQ/AZ are not effective therapies for outpatient
2021	Placebo: 4/83 (4.8%)	Placebo: 0/83	Placebo: 5/83 (6.0%)	treatment of SARV-CoV-2 infection."

	HCC	Ç	Place	bo		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Weight M-H, Fixed, 95% Cl M-H, Fixed, 95		H, Fixed, 95%	CI		
Johnston 2021	2	71	4	83	16.5%	0.58 [0.11, 3.10]			-		
Reis 2021	8	214	11	227	47.7%	0.77 [0.32, 1.88]					
Skipper 2020	4	212	8	211	35.8%	0.50 [0.15, 1.63]			-		
Total (95% CI)		497		521	100.0%	0.64 [0.33, 1.23]			•		
Total events	14		23								
Heterogeneity: Chi²=	0.35, df =	2 (P=	0.84);	= 0%			0.01	0.1	<del>-  </del>	10	100
Test for overall effect:	Z = 1.33	(P = 0.1)	8)				0.01	0.1	HCQ Place		100

Fig. S8. Forest plot showing the risk of hospitalization for non-hospitalized COVID-19 patients treated with hydroxychloroquine.

	HCC	2	Place	bo		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
Johnston 2021	0	71	0	83		Not estimable			
Reis 2021	0	214	1	227	59.2%	0.35 [0.01, 8.63]	_		
Skipper 2020	1	212	1	211	40.8%	1.00 [0.06, 15.81]		+	
Total (95% CI)		497		521	100.0%	0.62 [0.08, 4.68]			
Total events	1		2						
Heterogeneity: Chi²=	0.23, df =	1 (P=	0.63); l <sup>2</sup> :	= 0%			L	0.1 1 10	1000
Test for overall effect:	Z = 0.47	(P = 0.6)	64)				0.001	0.1 1 10 HCQ Placebo	1000

Fig. S9. Forest plot showing the risk of death for non-hospitalized COVID-19 patients treated with hydroxychloroquine.

	HCC	2	Place	bo		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 959	% CI	
Johnston 2021	5	71	5	83	13.6%	1.17 [0.35, 3.88]		-		
Reis 2021	46	207	46	220	41.7%	1.06 [0.74, 1.53]		+		
Skipper 2020	92	212	46	211	44.7%	1.99 [1.48, 2.68]		-		
Total (95% CI)		490		514	100.0%	1.43 [0.85, 2.38]		•		
Total events	143		97							
Heterogeneity: Tau² = Test for overall effect:				P = 0.0	3); I² = 72	%	0.01 0.1	Placebo HCQ	10	100

Fig. S10. Forest plot showing the risk of any adverse events for non-hospitalized COVID-19 patients treated with hydroxychloroquine.

# Hydroxychloroquine as treatment for hospitalized patients with COVID-19

Table S8. Blinded, placebo-controlled, randomized clinical trials evaluating the efficacy and safety of hydroxychloroquine as treatment for hospitalized patients with COVID-19.

Author	Study	Country	Protocol and Phase	Population	Intervention	Control	Outcomes of interest (Time of evaluation)
Dubée 2021	Hydroxychloroquine in mild-to-moderate COVID-19: a placebo- controlled double- blind trial	France	NCT04325893 (Phase 3)	<ul> <li>Non-critically ill patients with COVID-19 requiring hospitalization with/without need for supplemental oxygen. Cases requiring oxygen therapy &gt;3 L/min or intensive care were excluded.</li> <li>HCQ group: median age 76y (range 60-85). Sex: 52.0% male. Medical conditions: hypertension 52.0%, diabetes 16.0%, heart disease 27.2%. Concomitant medications: corticosteroids 10.4%.</li> <li>Placebo: median age 78y (range 57-87). Sex: 44.8% male. Medical conditions: hypertension 54.8%, diabetes 18.6%, heart disease 30.7%. Concomitant medications: corticosteroids 8.8%.</li> </ul>	HCQ 200mg, 2x/day in the first day + 200mg, 2x/day for 8 days (n = 124)	Placebo (n = 123)	Need for mechanical ventilation, death, and adverse events (14 and 28 days)
Hernandez- Cardenas 2021	Hydroxychloroquine for the treatment of severe respiratory infection by COVID- 19: a randomized controlled trial	Mexico	NCT04315896 (Phase 3)	<ul> <li>Critically ill patients with COVID-19 requiring hospitalization with/without need for mechanical ventilation.</li> <li>HCQ group: mean age 50y (SD 11). Sex: 82.1% male. Medical conditions: hypertension 16.0%, diabetes 18.9%. Concomitant medications: corticosteroids 51.9%, anticoagulants 54.7%, tocilizumab 2.8%.</li> <li>Placebo: mean age 49y (SD 11). Sex: 68.5% male. Medical conditions: hypertension: 17.6%, diabetes 13.0%. Concomitant medications: corticosteroids 48.1%, anticoagulants 57.4%, tocilizumab 1.9%.</li> </ul>	HCQ 200mg, 2x/day for 10 days (n = 106)	Placebo (n = 108)	Days of hospitalization, death, and adverse events (30 days)
Gonzalez 2021	Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial	Mexico	NCT04391127 (Phase 3)	<ul> <li>Non-critically ill patients with COVID-19 requiring hospitalization with need for supplemental oxygen. Cases requiring oxygen therapy &gt;10</li></ul>	HCQ 400mg, 2x/day in the first day + 200mg, 2x/day for 4 days (n = 33)	Placebo (n = 37)	Days of hospitalization, death, and adverse events (30 days)

Table S8 (continuation). Blinded, placebo-controlled, randomized clinical trials evaluating the efficacy and safety of hydroxychloroquine as treatment for hospitalized patients with COVID-19.

Author	Study	Country	Protocol and Phase	Population	Intervention	Control	Outcomes of interest (Time of evaluation)
Ulrich	Treating COVID-19	USA	NCT04369742	Non-critically ill patients with COVID-19 requiring hospitalization	HCQ 400mg, 2x/day in	Placebo	Need for mechanical
2020	With Hydroxychloroquine (TEACH): A Multicenter, Double- Blind Randomized Controlled Trial in Hospitalized Patients		(Phase 2)	<ul> <li>with/without need for supplemental oxygen. Cases requiring mechanical ventilation or intensive care on enrollment were excluded.</li> <li>HCQ group: mean age 66.5y (SD 16.4). Sex: 67.2% male. Medical conditions: hypertension 53.7%, diabetes 28.4%, heart disease 31.3%. Concomitant medications: corticosteroids 10.4%, anticoagulants 32.8%, remdesivir 1.5%, tocilizumab 4.5%.</li> <li>Placebo: mean age 65.8y (SD 16.0). Sex: 50.8% male. Medical conditions: hypertension 62.3%, diabetes 36.1%. Concomitant medications: corticosteroids 9.8%, anticoagulants 39.8%, remdesivir 0, tocilizumab 3.3%.</li> </ul>	the first day + 200mg, 2x/day for 4 days (n = 67)	(n = 61)	ventilation, days of hospitalization, death, and adverse events (14 and 30 days)
Self 2020	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID- 19: A Randomized Clinical Trial	USA	NCT04332991 (Phase 3)	<ul> <li>Critically and non-critically patients with COVID-19 requiring hospitalization with/without intensive care.</li> <li>HCQ group: median age 58y (range 45-69). Sex: 55.8% male. Medical conditions: hypertension 56.2%, diabetes 36.4%, heart disease 7.9%. Concomitant medications: corticosteroids 16.1%, remdesivir 23.1%, tocilizumab 4.1%.</li> <li>Placebo: median age 57y (range 43-68). Sex: 55.7% male. Medical conditions: hypertension 49.4%, diabetes 32.9%, heart disease 9.7%. Concomitant medications: corticosteroids 20.7%, remdesivir 20.3%, tocilizumab 7.2%.</li> </ul>	HCQ 400mg, 2x/day in the first day + 200mg, 2x/day for 4 days (n = 242)	Placebo (n = 237)	Need for mechanical ventilation, death, and adverse events (14 and 28 days)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Sample size calculation, power analysis, and early stopping for futility (operational bias)	Outcome measurements (information bias)	Conflict of interest
Dubée 2021	•	•	•	•	•	•	•	•	?
Gonzalez 2021	?	•	•	?	?	•	•	•	?
Hernandez-Cardenas 2021	•	•	•	•	•			•	?
Self 2020	•	•	•	•	•	•	•	•	?
Ulrich 2020	?	?	•	?	•	•	•	•	?

Fig. S11. Risk of bias assessment on the use of hydroxychloroquine as treatment for hospitalized patients with COVID-19.

Table S9. Individual results of studies evaluating the efficacy and safety of hydroxychloroquine as treatment for hospitalized patients with COVID-19.

Author	Days of hospitalization	Mechanical ventilation	Death	Any adverse events	Conclusion
Dubée	-	14 days	14 days	28 days	"Patients treated with hydroxychloroquine did not
2021		HCQ: 3/124 (2.4%)	HCQ: 6/124 (4.8%)	HCQ: 70/124 (56.5%)	experience better clinical or virological outcomes
		Placebo: 3/123 (2.4%)	Placebo: 6/123 (4.9%)	Placebo: 61/120 (50.8%)	than those receiving the placebo."
		28 days	28 days		
		HCQ: 3/124 (2.4%)	HCQ: 6/124 (4.8%)		
		Placebo: 4/123 (3.3%)	Placebo: 11/123 (8.9%)		
Hernandez-Cardenas	HCQ: 17.8 ± 11.0 days*	_	30 days	Data on adverse events were unclear	"No beneficial effect or significant harm could be
2021	Placebo: 18.1 ± 12.0 days		HCQ: 40/106 (37.7%)	and could not be extracted	demonstrated in our randomized controlled trial
2021	1 accso. 10.1 ± 12.0 days		Placebo: 44/108 (40.7%)	and could not be extracted	including 214 patients, using relatively low doses of HCQ compared with placebo in hospitalized patients with severe COVID-19."
Gonzalez	HCQ: 7 (3 – 9) days**	-	30 days	Data on adverse events were unclear	"In non-critical hospitalized patients with COVID-19
2021	Placebo: 5 (4 –7) days		HCQ: 2/33 (6.1%) Placebo: 6/37 (16.2%)	and could not be extracted	pneumonia, neither ivermectin nor hydroxychloroquine decreases the number of in- hospital days, respiratory deterioration, or deaths."
Ulrich	HCQ: 9.8 ± 10.3 days*	14 days	14 days	30 days	"In hospitalized patients with COVID-19, our data
2020	Placebo: $6.8 \pm 5.9$ days	HCQ: 5/67 (7.5%)	HCQ: 3/67 (4.5%)	HCQ: 38/67 (56.7%)	suggest that HCQ does not prevent severe
		Placebo: 4/61 (6.6%)	Placebo: 5/61 (8.2%)	Placebo: 36/61 (59.0%)	outcomes or improve clinical scores."
		30 days	30 days		
		HCQ: 5/67 (7.5%)	HCQ: 7/67 (10.4%)		
		Placebo: 3/61 (4.9%)	Placebo: 6/61 (9.8%)		
Self	-	14 days	14 days	28 days	"These findings do not support the use of
2020		HCQ: 18/242 (7.4%)	HCQ: 18/242 (7.4%)	HCQ: 14/242 (5.8%)	hydroxychloroquine for treatment of COVID-19
		Placebo: 24/237 (10.1%)	Placebo: 14/237 (5.9%)	Placebo: 11/237 (4.6%)	among hospitalized adults."
		28 days	28 days		
		HCQ: 11/242 (4.5%)	HCQ: 25/242 (10.3%)		
		Placebo: 12/237 (5.1%)	Placebo: 25/237 (10.5%)		

HCQ, hydroxychloroquine. \* Data were reported in mean and standard deviation. \*\* Data were reported in median and interquartile range.

	HCC	Q	Place	bo		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
Dubée 2021	3	124	3	123	9.6%	0.99 [0.20, 4.82]			
Self 2020	18	242	24	237	77.1%	0.73 [0.41, 1.32]		-	
Ulrich 2020	5	67	4	61	13.3%	1.14 [0.32, 4.05]			
Total (95% CI)		433		421	100.0%	0.81 [0.49, 1.34]		•	
Total events	26		31						
Heterogeneity: Chi²=	0.45, df =	2 (P=	0.80);	= 0%			0.01	0.1 1	10 100
Test for overall effect:	Z = 0.81	(P = 0.4)	12)				0.01	HCQ Placebo	10 100

Fig. S12. Forest plot showing the risk of mechanical ventilation at two weeks for hospitalized COVID-19 patients treated with hydroxychloroguine.

	HCC	2	Place	bo		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI			
Dubée 2021	3	124	4	123	20.8%	0.74 [0.17, 3.26]	·]	
Self 2020	11	242	12	237	62.9%	0.90 [0.40, 1.99]	] —	
Ulrich 2020	5	67	3	61	16.3%	1.52 [0.38, 6.08]	1	
Total (95% CI)		433		421	100.0%	0.97 [0.52, 1.80]	1 🔸	
Total events	19		19					
Heterogeneity: Chi² = 0.56, df = 2 (P = 0.76); l² = 0%							0.01 0.1 1 10 100	
Test for overall effect:	Z = 0.11	(P = 0.9)	91)				HCQ Placebo	

Fig. S13. Forest plot showing the risk of mechanical ventilation at four weeks for hospitalized COVID-19 patients treated with hydroxychloroguine.




Fig. S14. Forest plot showing the risk of death at two weeks for hospitalized COVID-19 patients treated with hydroxychloroquine.




Fig. S15. Forest plot showing the risk of death at four weeks for hospitalized COVID-19 patients treated with hydroxychloroquine.

	HCC	2	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Dubée 2021	70	124	61	120	56.0%	1.11 [0.88, 1.40]	<del>-</del>
Self 2020	14	242	11	237	10.0%	1.25 [0.58, 2.69]	<del></del>
Ulrich 2020	38	67	36	61	34.0%	0.96 [0.71, 1.29]	<del></del>
Total (95% CI)		433		418	100.0%	1.07 [0.89, 1.29]	•
Total events	122		108				
Heterogeneity: Chi²=	0.76, df =	2 (P=	0.68); l² =	= 0%			0.2 0.5 1 2 5
Test for overall effect:	Z = 0.75 (	(P = 0.4)	15)				Placebo HCQ

Fig. S16. Forest plot showing the risk of any adverse events for hospitalized COVID-19 patients treated with hydroxychloroquine.

Table S10. Sensitivity analysis of studies evaluating the efficacy and safety of hydroxychloroquine as treatment for hospitalized patients with COVID-19.

Outcomes	RR (95% CI)		Risk of bias	Inconsistency	Indirectness	Imprecision	Influence of small trials	Large effect	Quality of evidence
Death (4 weeks)									
Peer-reviewed studies	0.88 (0.58 to 1.33)	0%	Not serious	Not serious	Not serious	Serious	Not serious	No	$\oplus \oplus \oplus \bigcirc$
Non-peer reviewed studies	0.80 (0.42 to 1.55)	24%	Not serious	Not serious	Not serious	Serious	Not serious	No	$\oplus \oplus \oplus \bigcirc$

Certainty: ⊕ very-low; ⊕⊕ low; ⊕⊕⊕ moderate; ⊕⊕⊕⊕ high.




Fig. S17. Forest plot showing the risk of any adverse events for patients treated with hydroxychloroquine.




Fig. S18. Forest plot showing the risk of serious adverse events for patients treated with hydroxychloroquine.



Fig. S19. Forest plot showing the risk of QTc interval > 500ms for patients treated with hydroxychloroquine.




Fig. S20. Forest plot showing the risk of cardiac manifestations for patients treated with hydroxychloroguine.




Fig. S21. Forest plot showing the risk of gastrointestinal symptoms for patients treated with hydroxychloroguine.




Fig. S22. Forest plot showing the risk of headache for patients treated with hydroxychloroguine.




Fig. S23. Forest plot showing the risk of skin rash for patients treated with hydroxychloroquine.




Fig. S24. Forest plot showing the risk of neurologic reactions for patients treated with hydroxychloroquine.